A patient hears one term from their neurologist and a completely different one from a hospital pamphlet, then wonders whether “plasmapheresis” and “plasma exchange” describe the same appointment or two different treatments entirely. That confusion is the whole reason the plasma exchange vs plasmapheresis question keeps coming up – the two words get used almost interchangeably in clinic conversations, patient handouts, and even some published research, yet a real technical distinction sits underneath the overlap.
Below, we untangle what plasmapheresis actually covers as a category, how therapeutic plasma exchange sits inside it as one specific application, where clinicians actually draw a line between the two in daily practice, and what the research literature says about their shared roles in treating autoimmune disease, neurological disorders, and stubborn cholesterol problems.
What Is Plasmapheresis?
Strip plasmapheresis down to its core, and it’s simply a separation technique: pulling plasma – blood’s liquid fraction – away from its cellular passengers (red cells, white cells, platelets). Clinics accomplish that split one of two ways. Centrifugation spins whole blood fast enough that heavier cells sink away from lighter plasma. Membrane filtration instead pushes blood across a filter fine enough to hold cells back while letting plasma pass through.
What happens to that plasma afterward is where things branch. A center might collect it for donation, treat it and hand it back to the same patient, or discard it entirely and swap in a substitute fluid. That branching is precisely why “plasmapheresis” functions less like a single procedure and more like an umbrella category – the term names the separation step, full stop, and stays silent on what comes next. For a deeper walkthrough of the equipment and what a session actually looks like, see our complete guide to plasmapheresis.
What Is Plasma Exchange (Therapeutic Plasma Exchange)?
Therapeutic plasma exchange (TPE) – the fuller, more precise name for plasma exchange – takes that separated plasma one step further: instead of returning it, clinicians discard it and replace it with a substitution fluid, commonly albumin solution or saline, and occasionally fresh frozen plasma when bleeding risk is a factor. The patient’s own blood cells go back into circulation along with whatever replacement fluid was chosen.
Why bother removing plasma at all? Because in certain diseases, the plasma itself is the problem – it’s carrying autoantibodies, immune complexes, excess LDL-bound cholesterol, or other circulating culprits that a clinician wants out of the bloodstream. A session generally runs one to three hours through an IV or catheter, with staff tracking fluid balance, electrolytes, and clotting factors the entire time. The American Society for Apheresis (ASFA) has gone as far as formally ranking TPE indications by disease and evidence strength, which says something about how entrenched this specific application has become in clinical medicine (Connelly-Smith et al., Journal of Clinical Apheresis, 2023).
Key Differences Explained: Plasma Exchange vs Plasmapheresis
At bottom, the plasma exchange vs plasmapheresis question is a matter of scope, not competing definitions. Plasmapheresis is the umbrella process – plasma gets separated from cells, nothing more is implied. Plasma exchange narrows that down to one specific version, tacking on two additional steps: the separated plasma gets discarded, then replaced with substitute fluid.
Flip that relationship around and it reads clearly: every plasma exchange session is technically an act of plasmapheresis, but plenty of plasmapheresis sessions never become plasma exchange. Donor plasmapheresis is the clearest example – the collected plasma usually gets stored for future use rather than discarded and replaced on the spot. That’s the reasoning behind treating plasmapheresis vs plasma exchange as a strict either/or split in some technical writing, even though everyday usage rarely bothers to separate them.
In real clinical settings, most providers reach for “plasmapheresis” as informal shorthand for the therapeutic procedure, even when plasma exchange with fluid replacement is precisely what they mean. Tell a patient they’re scheduled for “plasmapheresis” to manage a lupus flare or a nerve disorder, and nearly every time, what they’re actually receiving is therapeutic plasma exchange. Pinning down the difference between plasma exchange and plasmapheresis mostly earns its keep in research papers and informed-consent paperwork, where precision matters – day to day, patients are typically undergoing the identical procedure no matter which label gets used.
Shared Clinical Uses
Since plasma exchange is simply the therapeutic branch of plasmapheresis, both terms end up attached to the same roster of established uses. TPE has been a treatment option for decades in conditions where something circulating in the plasma appears to be fueling disease.
Autoimmune and hematologic conditions. For thrombotic thrombocytopenic purpura (TTP), a rare and dangerous blood disorder, TPE is regarded as first-line treatment rather than a fallback option. In a landmark trial, patients who underwent plasma exchange survived at meaningfully higher rates than those who received plasma infusion alone (Rock et al., New England Journal of Medicine, 1991) – a finding that reshaped how TTP is managed and helped make apheresis a standard part of the treatment protocol rather than an experimental add-on. Readers interested in broader autoimmune applications – including lupus complications and vasculitis – can find more detail in our piece on how plasmapheresis helps autoimmune conditions.
Neurological disorders. Severe, acute Guillain-Barré syndrome – where the immune system turns on peripheral nerves – has relied on TPE for years. A Cochrane systematic review found that plasma exchange sped up recovery and cut the need for mechanical ventilation compared with supportive care alone (Chevret et al., Cochrane Database of Systematic Reviews, 2017). Separately, the multi-year AMBAR trial tested plasma exchange with albumin replacement in people with mild-to-moderate Alzheimer’s disease and reported slower cognitive and functional decline over 14 months compared with a sham-treated group (Boada et al., Alzheimer’s & Dementia, 2020).
Hypercholesterolemia. When medication alone can’t adequately control familial hypercholesterolemia, lipoprotein apheresis – a targeted variant of plasma exchange or selective filtration – physically strips excess LDL cholesterol from the blood. A systematic review of this approach documented consistent LDL reductions across the studies examined, along with hints of lower cardiovascular event rates in certain patient groups (Wang et al., Journal of the American Heart Association, 2016).
The Evidence: What Research Shows
The strongest evidence for TPE clusters around diseases with a clearly identifiable, physically removable plasma component. The 1991 TTP trial remains the textbook example: patients on plasma exchange fared noticeably better than those given plasma infusion alone, which helped establish that the removal-and-replacement mechanism – not simply plasma volume – is what drives the benefit.
Guillain-Barré syndrome tells a similar story across multiple randomized trials: earlier treatment tracks with better outcomes, and plasma exchange performs comparably to intravenous immunoglobulin, the other major therapy in this space. Hypercholesterolemia evidence leans more mechanistic – LDL apheresis consistently lowers circulating cholesterol, and some research suggests that translates into lower cardiovascular risk over time, though much of that supporting data comes from cohort and registry studies rather than large placebo-controlled trials.
ASFA’s guidelines pull this evidence landscape together by grading dozens of disease indications according to strength of evidence, giving clinicians and patients alike a reference point for where TPE is firmly established versus where it remains more investigational (Connelly-Smith et al., 2023).
Safety Considerations
Under proper clinical supervision, TPE tends to be well-tolerated, but it isn’t risk-free, and monitoring matters throughout. Documented risks include drops in blood pressure during or shortly after treatment, electrolyte shifts (calcium disturbances are especially common given the citrate anticoagulants typically used), allergic reactions to replacement fluids like albumin or fresh frozen plasma, and infection risk tied to catheter or IV access.
Certain patients – those with bleeding disorders, unstable cardiovascular status, active systemic infection, or known sensitivities to replacement fluid ingredients – may not be good candidates and need careful evaluation before moving forward. Because TPE strips out therapeutic drugs and clotting factors right alongside the harmful plasma components, medication schedules and dosing often require adjustment around each session, and clinicians frequently coordinate with a patient’s other prescribing physicians to plan timing accordingly. A thorough intake, covering bloodwork and a full medication review, should come before any plasma exchange procedure gets underway, and follow-up labs afterward help confirm that electrolytes and clotting parameters have returned to a safe baseline.
Frequently Asked Questions
What is the actual difference between plasma exchange and plasmapheresis?
Plasmapheresis describes the general act of separating plasma from blood cells. Plasma exchange is the specific therapeutic version of that process – the separated plasma gets discarded and swapped out for a substitute fluid such as albumin or saline.
Is plasma exchange the same procedure as plasmapheresis?
When someone mentions “plasmapheresis” in a treatment context, they’re almost always describing what’s technically plasma exchange. The plasmapheresis vs plasma exchange distinction lives more in terminology than in any real difference in what a patient goes through.
Why do doctors use the terms plasmapheresis and plasma exchange interchangeably?
Because in therapeutic settings, the two labels nearly always point to the same procedure. Technically, plasmapheresis names the general process and plasma exchange names its specific application, but everyday clinical conversation rarely preserves that line.
What conditions are treated with plasma exchange or plasmapheresis?
Established applications include autoimmune and hematologic disorders such as thrombotic thrombocytopenic purpura, neurological conditions like Guillain-Barré syndrome and myasthenia gravis, and familial hypercholesterolemia that doesn’t respond well enough to medication, among other ASFA-categorized indications.
How long does a plasma exchange session take?
Most therapeutic plasma exchange sessions run roughly one to three hours, delivered through an IV or catheter, with vital signs, fluid balance, and electrolytes monitored closely throughout.
What replacement fluids are used during plasma exchange?
Albumin solution and normal saline are the most common choices, sometimes combined. Fresh frozen plasma sometimes replaces them, particularly when bleeding risk or clotting factor deficiencies are a concern, as with TTP.
Is plasma exchange safe?
Under clinical supervision, TPE is generally well-tolerated, though real risks exist – blood pressure swings, electrolyte imbalances, allergic reactions to replacement fluids, and infection risk at the access site among them. A qualified provider should weigh individual risk factors before treatment begins.
Does insurance cover plasma exchange or plasmapheresis?
Coverage typically hinges on whether the procedure targets an established, evidence-backed indication – the kind categorized in ASFA guidelines – versus a more investigational use. Confirming coverage directly with an insurer and treating clinic before scheduling is the safest approach.
Key Takeaways
- The plasma exchange vs plasmapheresis question is ultimately about scope: plasmapheresis names the general process of separating plasma from blood cells, while plasma exchange is the specific therapeutic application that removes and replaces that plasma.
- Every plasma exchange procedure counts as plasmapheresis, but not every plasmapheresis procedure includes the removal-and-replacement steps that define plasma exchange.
- Day to day, plasmapheresis vs plasma exchange is mostly a terminology nuance rather than a difference in the actual procedure a patient undergoes.
- Therapeutic plasma exchange has established, evidence-supported roles in autoimmune and hematologic conditions like TTP, neurological disorders like Guillain-Barré syndrome, and familial hypercholesterolemia.
- Research evidence is strongest for diseases with a clearly identifiable, removable plasma component, and evidence strength varies noticeably by condition.
- TPE carries real risks – including blood pressure changes, electrolyte imbalances, and infection risk – and calls for clinical supervision and individualized evaluation.
- ASFA guidelines offer a formal, evidence-graded framework distinguishing established from investigational indications for plasma exchange.
Weighing options for an autoimmune, neurological, or lipid-related condition often means understanding exactly how these two terms relate – explore Ways2Well’s approach to plasma exchange and plasmapheresis, or schedule a consultation to talk through whether either option fits your individual health picture.
References
- Connelly-Smith L, Alquist CR, Aqui NA, et al. “Guidelines on the Use of Therapeutic Apheresis in Clinical Practice – Evidence-Based Approach from the Writing Committee of the American Society for Apheresis: The Ninth Special Issue.” Journal of Clinical Apheresis, 2023;38(2):77–278. DOI: https://doi.org/10.1002/jca.22043
- Rock GA, Shumak KH, Buskard NA, et al. “Comparison of Plasma Exchange with Plasma Infusion in the Treatment of Thrombotic Thrombocytopenic Purpura.” New England Journal of Medicine, 1991;325(6):393–397. DOI: https://doi.org/10.1056/NEJM199108083250604
- Chevret S, Hughes RAC, Annane D. “Plasma exchange for Guillain-Barré syndrome.” Cochrane Database of Systematic Reviews, 2017;2:CD001798. DOI: https://doi.org/10.1002/14651858.CD001798.pub3
- Wang A, Richhariya A, Gandra SR, et al. “Systematic Review of Low-Density Lipoprotein Cholesterol Apheresis for the Treatment of Familial Hypercholesterolemia.” Journal of the American Heart Association, 2016;5(7):e003294. DOI: https://doi.org/10.1161/JAHA.116.003294
- Boada M, López OL, Olazarán J, et al. “A randomized, controlled clinical trial of plasma exchange with albumin replacement for Alzheimer’s disease: Primary results of the AMBAR Study.” Alzheimer’s & Dementia, 2020;16(10):1412–1425. DOI: https://doi.org/10.1002/alz.12137
Author: Ways2Well Editorial Team
Reviewed by: Scientific Advisory Board member